Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 250 versus RENOGRAFIN 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 250 versus RENOGRAFIN 76.
IOPAMIDOL-250 vs RENOGRAFIN-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a non-ionic, water-soluble, iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging procedures. It acts by increasing the radiodensity of blood vessels and organs.
Radiopaque contrast agent that attenuates X-rays by absorbing them due to its high iodine content, allowing visualization of vascular structures and organs during radiographic procedures.
1-2 mL/kg intravenously for contrast imaging, not to exceed 200 mL total; dose and rate vary by procedure and patient weight.
Intravenous administration of 50-100 mL (14.1-28.2 g iodine) as a single dose for angiography; dose varies by procedure and patient size.
None Documented
None Documented
Terminal half-life 1.5-2 hours in normal renal function; may extend to 5-10 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 1–2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <10 mL/min)
Renal: >90% unchanged via glomerular filtration; biliary/fecal: <2%
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<5%)
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent